Carvedilol

The main ingredient of this product is carvedilol. Chemical name: (±)-1-(9H-carbazole-4-oxy)-3-[2-(2-methoxyphenoxyethyl)-amino]-2-propanol Chemical structure: Molecular formula: C24H26N2O4 Molecular weight: 406.49

1. Like other beta-blockers, carvedilol can also enhance the effects of other antihypertensive drugs (such as alpha-blockers) used in combination, or produce hypotension. When carvedilol is used in combination with diltiazem, some patients experience heart conduction block (the effect on hemodynamics is rare). However, like other drugs with beta-blocking effects, when carvedilol is used in combination with calcium channel blockers such as verapamil and diltiazem, the patient's electrocardiogram and blood pressure should be closely monitored, and intravenous combined use of such drugs is strictly prohibited. 2. When carvedilol is used in combination with digoxin in hypertensive patients, the steady-state blood concentration of digoxin will increase by about 16%. Therefore, the monitoring of digoxin blood concentration should be strengthened at the beginning stage of carvedilol use, the dose adjustment stage and when carvedilol is discontinued. 3. Before the end of the combined use of carvedilol and clonidine, carvedilol should be discontinued a few days before discontinuation of clonidine, and then clonidine should be gradually reduced until it is discontinued. 4. Carvedilol may enhance the effects of insulin or oral hypoglycemic drugs, while the symptoms and signs of hypoglycemia (especially tachycardia) may be masked or weakened and difficult to detect, so it is recommended to monitor blood glucose levels regularly. 5. When carvedilol is used in patients receiving mixed-function oxidase inducers such as rifampicin, the blood concentration of carvedilol may decrease. When it is used in patients receiving mixed-function oxidase inhibitors such as cimetidine, the blood concentration of carvedilol may increase, so attention should be paid. 6. When patients use carvedilol during anesthesia, the negative inotropic effect and hypotension caused by the synergistic effect of carvedilol and anesthetics should be closely observed. 7. The combined use of carvedilol and cardiac glycosides may prolong atrioventricular conduction time. 8. Cyclooxygenase inhibitors (such as acetylsalicylate, corticosteroids) can weaken the antihypertensive effect of carvedilol. 9. The plasma concentration of cyclosporine increases slightly after some renal transplant patients start carvedilol treatment, and the dose that needs to be adjusted for this varies greatly among different patients. Therefore, cyclosporine concentrations should be carefully monitored and the dose individualized in these patients.

The main ingredient of this product is carvedilol.

1. CYP2D6 inhibitors There are no studies on the interaction between carvedilol and CYP2D6 inhibitors (such as quinidine, fluoxetine, paroxetine), but it is expected that this type of drug will increase the concentration of carvedilol dextrorotatory body. Retrospective analysis shows that the incidence of dizziness is high in patients with poor 2D6 metabolizers during the dosage increase period, which is speculated to be due to the vasodilatory effect of the dextrorotatory body with alpha-blocking activity due to the increased concentration. 2. Drugs that deplete catecholamines When carvedilol is taken with drugs that deplete catecholamines (such as reserpine, monoamine oxidase inhibitors), the patient must be closely observed for hypotension and/or severe bradycardia symptoms. 3. Digoxin When carvedilol and digoxin are taken at the same time, the blood digoxin concentration can be increased by 15%. 4. When clonidine is taken at the same time as carvedilol, it may enhance the effect of lowering blood pressure and slowing heart rate. Carvedilol should be discontinued a few days before clonidine is discontinued, and then clonidine should be gradually reduced to discontinuation. 5. Cyclosporine increases the trough concentration of cyclosporine in the blood, and the dose of cyclosporine needs to be reduced to maintain it within the therapeutic concentration. It is recommended to closely monitor the concentration of cyclosporine after starting carvedilol treatment and adjust the dose of cyclosporine appropriately. 6. The liver metabolism inducer and inhibitor remifentanil reduces the plasma concentration of carvedilol by 70%. Cimetidine increases the AUC of carvedilol by 30%, but the Cmax does not change. 7. There are reports of conduction disorders when calcium antagonists are used in combination with diltiazem. It is recommended that, like other beta-receptor blockers, electrocardiograms and blood pressure should be monitored when used in combination with verapamil or diltiazem-type calcium antagonists. 8. Insulin or oral hypoglycemic drugs with beta-receptor blocking activity may enhance the blood sugar-lowering effect of insulin or oral hypoglycemic drugs, so blood sugar needs to be monitored.

Molecular weight: C24H26N2O4

1. Like other beta-blockers, carvedilol can also enhance the effects of other antihypertensive drugs (such as alpha-blockers) used in combination, or produce hypotension. When carvedilol is used in combination with diltiazem, some patients experience heart conduction block (the effect on hemodynamics is rare). However, like other drugs with beta-blocking effects, when carvedilol is used in combination with calcium channel blockers such as verapamil and diltiazem, the patient's electrocardiogram and blood pressure should be closely monitored, and intravenous co-use of such drugs is strictly prohibited. 2. When carvedilol and digoxin are used in combination in hypertensive patients, the steady-state blood concentration of digoxin will increase by about 16%. Therefore, the monitoring of digoxin blood concentration should be strengthened at the beginning stage of carvedilol use, the dose adjustment stage and when carvedilol is discontinued. 3.